⌕
Arcus Biosciences · RCUS · NYSE
Tenet 31 · Weak
Compare
$16.39−2.79%At closeTenet 31 · Weak
$16.39−0.47 (−2.79%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Arcus Biosciences (RCUS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

20 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 36% below its peak, net margin −142.9%. Worth your attention in FY25: Share count (+45.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼4.3%
247.0
FY21→FY25CAGR −10.4%/yr
Net income ($M)▼24.7%
−353.0
FY21→FY25CAGR —
Free cash flow ($M)▼175.0%
−484.0
FY21→FY25CAGR —
Diluted EPS▼4.8%
−3.29
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+45.1%

74.0mn → 107.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$2.0M

−66.7% YoY in FY25 · 0.8% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)247.0Revenue0.0COGS−523.0R&D−110.0SG&A−386.0Op income33.0Tax & other−353.0Net income

-143¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -142.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
100.0247.0258.0117.0112.0383.0▼4.3%−10.4%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A383.0——
Research & development
473.0523.0448.0340.0288.0257.0▲16.7%+19.4%
Selling, general & admin
102.0110.0120.0117.0104.072.0▼8.3%+11.2%
Total operating expenses
575.0633.0588.0457.0392.0329.0▲7.7%+17.8%
Operating incomefeeds ROC rank
−475.0−386.0−330.0−340.0−280.054.0▼17.0%—
Other income, net
22.033.048.039.014.01.0——
Pretax income
−453.0−353.0−282.0−301.0−266.055.0▼25.2%—
Income tax
—0.01.06.01.02.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−453.0−353.0−283.0−307.0−267.053.0▼24.7%—
Per share
Diluted EPSbuyback-sensitive
−3.62−3.29−3.14−4.15−3.71—▼4.8%—
Diluted shares (mn)
127.40107.4090.1074.0072.0074.00▲19.2%+9.8%
Margins
Gross margin
—A—A—A—A—A100.0%——
Operating margin
−475.0%−156.3%−127.9%−290.6%−250.0%14.1%▼28.4pp−170.4pp
Net margin5th pct in Healthcare
−453.0%−142.9%−109.7%−262.4%−238.4%13.8%▼33.2pp−156.8pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Arcus Biosciences' revenue last fiscal year?

Arcus Biosciences reported revenue of $247.0M in fiscal 2025, down 4.3% from fiscal 2024.

What was Arcus Biosciences' net income?

Arcus Biosciences reported net income of −$353.0M in fiscal 2025, a net margin of −142.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.